BeiGene trial investigator Jennifer Brown of Dana-Farber Cancer Institute presents the ALPINE results at ASH on Dec. 13 in New Orleans (Photo: Assistant editor Paul Schloesser for Endpoints News)
December 13, 2022 10:00 AM ESTUpdated 01:06 PM
R&D

#ASH22: BeiGene's BTK in­hibitor shows su­pe­ri­or­i­ty to Ab­b­Vie, J&J block­buster in PFS

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

NEW OR­LEANS — As the last six ab­stracts were pre­sent­ed at the Amer­i­can So­ci­ety of Hema­tol­ogy on Tues­day, BeiGene sought to es­tab­lish that its BTK in­hibitor is now prac­tice-chang­ing.

The phar­ma re­leased more da­ta from its Phase III ALPINE tri­al Tues­day morn­ing, show­ing that Brukin­sa (zanubru­ti­nib) beat Im­bru­vi­ca (ibru­ti­nib) head to head on met­rics in pro­gres­sion-free sur­vival and safe­ty in pa­tients with re­lapsed/re­frac­to­ry CLL or SLL, al­so known as small lym­pho­cyt­ic lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

In rare move, Colom­bia is­sues com­pul­so­ry li­cense for HIV med­i­cine in ef­fort to ex­pand ac­cess

A service from the Financial Times